SOL-GEL TECHN. IS-10
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopust… Read more
SOL-GEL TECHN. IS-10 (4SG) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, SOL-GEL TECHN. IS-10 (4SG) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SOL-GEL TECHN. IS-10 - Net Assets Trend (None–None)
This chart illustrates how SOL-GEL TECHN. IS-10's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SOL-GEL TECHN. IS-10 (None–None)
The table below shows the annual net assets of SOL-GEL TECHN. IS-10 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SOL-GEL TECHN. IS-10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SOL-GEL TECHN. IS-10 Competitors by Market Cap
The table below lists competitors of SOL-GEL TECHN. IS-10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ocumetics Technology Corp
OTCQB:OTCFF
|
$18.47 Million |
|
KEBNI AB SER.B
F:KEN
|
$18.47 Million |
|
Guillemot Corporation S.A.
PA:GUI
|
$18.47 Million |
|
Baydoner Restoranlari A.S.
IS:BYDNR
|
$18.48 Million |
|
Ananda Development Public Company Limited
BK:ANAN
|
$18.46 Million |
|
Wider Planet Inc.
KQ:321820
|
$18.44 Million |
|
Heramed Ltd
AU:HMD
|
$18.44 Million |
|
Intrusion Inc
NASDAQ:INTZ
|
$18.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SOL-GEL TECHN. IS-10's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SOL-GEL TECHN. IS-10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SOL-GEL TECHN. IS-10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SOL-GEL TECHN. IS-10's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SOL-GEL TECHN. IS-10 (4SG) | €- | N/A | N/A | $18.46 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |